Related references
Note: Only part of the references are listed.Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes
Matthias Gehringer et al.
CHEMMEDCHEM (2014)
Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring
Kai Zhu et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
Janus kinase inhibitors in autoimmune diseases
John J. O'Shea et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Design and synthesis of tricyclic cores for kinase inhibition
Stacy Van Epps et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
Targeting kinases: a new approach to treating inflammatory rheumatic diseases
David L. Simmons
CURRENT OPINION IN PHARMACOLOGY (2013)
Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid Arthritis
Lesley J. Scott
DRUGS (2013)
Lead identification of novel and selective TYK2 inhibitors
Jun Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis
Andrew L. Rankin et al.
JOURNAL OF IMMUNOLOGY (2013)
Comprehensive review of JAK inhibitors in myeloproliferative neoplasms
Mohamad Bassam Sonbol et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans
Erica K. Evans et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2012)
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Roy Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2012)
Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors
Janusz J. Kulagowski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor
Maria A. Argiriadi et al.
BMC STRUCTURAL BIOLOGY (2012)
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Flavio Solca et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Minimum Significant Ratio of Selectivity Ratios (MSRSR) and Confidence in Ratio of Selectivity Ratios (CRSR): Quantitative Measures for Selectivity Ratios Obtained by Screening Assays
Eric R. Goedken et al.
JOURNAL OF BIOMOLECULAR SCREENING (2012)
Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
Claude Haan et al.
CHEMISTRY & BIOLOGY (2011)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Targeted covalent drugs of the kinase family
Juswinder Singh et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
Jill E. Chrencik et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
Covalent Modifiers: An Orthogonal Approach to Drug Design
Michele H. Potashman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
Neal K. Williams et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Targeting innate immunity protein kinase signalling in inflammation
Matthias Gaestel et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase
Wooyoung Hur et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)
Michael P. Clark et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Jak2: normal function and role in hematopoietic disorders
James N. Ihle et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
The JAK-STAT signaling pathway: Input and output intergration
Peter J. Murray
JOURNAL OF IMMUNOLOGY (2007)
Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3
Jack J. Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
The minimum significant ratio: A statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies
BJ Eastwood et al.
JOURNAL OF BIOMOLECULAR SCREENING (2006)
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor
IS Lucet et al.
BLOOD (2006)
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog
TJ Boggon et al.
BLOOD (2005)
JAK protein kinase inhibitors
JE Thompson
DRUG NEWS & PERSPECTIVES (2005)
Likelihood-enhanced fast translation functions
AJ McCoy et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2005)
Likelihood-enhanced fast rotation functions
LC Storoni et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4
WT Watford et al.
IMMUNOLOGICAL REVIEWS (2004)
IL-12 and IL-23: master regulators of innate and adaptive immunity
CL Langrish et al.
IMMUNOLOGICAL REVIEWS (2004)
The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models
E Kudlacz et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
The Janus kinases (Jaks)
K Yamaoka et al.
GENOME BIOLOGY (2004)
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
PS Changelian et al.
SCIENCE (2003)
Regulation of JAK-STAT signalling in the immune system
K Shuai et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Photochemical preparation of a pyridone containing tetracycle: A Jak protein kinase inhibitor
JE Thompson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002)
Irreversible inhibitors of the erbB family of protein tyrosine kinases
WA Denny
PHARMACOLOGY & THERAPEUTICS (2002)
Pushing the boundaries of molecular replacement with maximum likelihood
RJ Read
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2001)
STAT proteins and transcriptional responses to extracellular signals
CM Horvath
TRENDS IN BIOCHEMICAL SCIENCES (2000)
Share Paper
